Skip to content

PTSD sleep and nightmare treatment

TL;DR — Nightmares and insomnia can remain disabling even when total PTSD symptoms improve. Prazosin’s evidence is heterogeneous: two small early veteran trials were positive (Raskind 2003, PMID 12562588) (Raskind 2007, PMID 17069768), but a 13-centre trial of 304 veterans found no benefit on nightmares, sleep quality or global change at 10 or 26 weeks (Raskind 2018, PMID 29414272). That trial estimated between-group changes of 0.2 (95% CI −0.3 to 0.8) on CAPS nightmare item and 0.1 (−0.9 to 1.1) on PSQI at week 10. Imagery rehearsal and CBT for insomnia are non-drug options, with protocol and population variation.

Phenotyping

Nightmare frequency/distress, insomnia, sleep-disordered breathing, REM behaviour, medication/substance effects and circadian disruption require separation. A global sleep score can hide different mechanisms.

Prazosin contradiction

The later, much larger null trial does not erase earlier positive trials; together they imply heterogeneity, contextual effects or false-positive early estimates (Raskind 2003, PMID 12562588) (Raskind 2007, PMID 17069768) (Raskind 2018, PMID 29414272, NCT00532493). The contradiction survives at synthesis level, which is why it is content rather than an error to correct. Narrative reviews written before and around the large trial concluded that the accumulated open-label and randomized literature supported prazosin for nightmares and sleep (Green 2014, PMID 25036580) (Simon 2017, PMID 27432823). A meta-analysis of seven prazosin and eight IRT trials (N=1,078) estimated prazosin effects of g=0.61 on nightmare frequency, g=0.81 on post-traumatic stress symptoms and g=0.85 on sleep quality relative to control, with no significant difference from IRT on any outcome, and argued that downgrading prazosin on the strength of one trial was premature (Yücel 2020, PMID 31855732). A 29-trial network meta-analysis of 14 interventions in 2,214 trauma survivors likewise identified prazosin and IRT as the only two effective treatments for trauma-related nightmares (Zhang 2022, PMID 35661755). A third randomized trial in 67 active-duty soldiers returned from Iraq and Afghanistan was also positive on nightmares, sleep quality and global function before the large null trial (Raskind 2013, PMID 23846759). The candidate responder marker to come out of that trial is pretreatment blood pressure: in a secondary analysis of its 32 prazosin and 35 placebo participants, each 10-mm Hg higher baseline standing systolic pressure predicted an additional 14-point CAPS reduction under prazosin (P=.002), with no corresponding signal under placebo (Raskind 2016, PMID 27320368); the marker was questioned in a PTSD-with-alcohol-use-disorder sample (Manhapra 2019, PMID 30143236). The evidence gap is specific and dated: as of a live registry and PubMed check on 2026-09-02, the prospective test of that marker — a phase 3 prazosin-versus-placebo trial explicitly designed around noradrenergic biomarkers (NCT03539614, n=87, primary completion recorded as 1 January 2026) — has completed primary data collection but has no results publication indexed in PubMed, so no prespecified prazosin-responder phenotype has yet been prospectively confirmed.

Imagery rehearsal

IRT rescripts recurrent nightmares while awake; protocols differ in exposure content, rehearsal dose and whether combined with CBT-I. The anchoring trial randomized 168 women in New Mexico — 95% with moderate-to-severe PTSD and 97% survivors of rape or other sexual assault — to three IRT sessions or waitlist, and reported large reductions in nights per week with nightmares (d=1.24, P<.001) and nightmares per week (d=0.85, P<.001) at 3- and 6-month follow-up, though only 114 of 168 completed follow-up (Krakow 2001, PMID 11476655). Pooled across eight IRT trials the effects are smaller than that single trial: g=0.51 on nightmare frequency, g=0.31 on post-traumatic stress symptoms and g=0.51 on sleep quality (Yücel 2020, PMID 31855732).

CBT-I and sequencing

Insomnia may be treated directly before, during or after trauma-focused therapy, and sequencing has now been tested both ways with divergent results. In 110 survivors of interpersonal violence with PTSD, depression and insomnia, CBT-I delivered before CPT produced greater 6-week reductions in insomnia, depression and CAPS scores than attention control, and greater 20-week reductions after CPT in all three, with effects larger for insomnia and depression than for PTSD (Pigeon 2022, PMID 34265777). In 94 veterans randomized to CBT-I integrated with prolonged exposure versus sleep hygiene plus PE, PTSD symptoms fell in both arms with no between-group difference (P=.844); only perceived quality of life favoured the CBT-I arm (Colvonen 2025, PMID 40488726). In the trauma-related-nightmare network meta-analysis, CBT-I, CBT-I+IRT, PE and IRT+PE did not separate from control on nightmare outcomes (Zhang 2022, PMID 35661755). Trials should therefore measure sleep and PTSD separately, because improvement in one does not guarantee the other.

Safety

Alpha-1 blockade can lower blood pressure; the large trial documented a 6.7-mm Hg greater supine systolic reduction (Raskind 2018, PMID 29414272). This is not dosing guidance.

Pooling warning

Meta-analyses mixing idiopathic nightmares, depression, anxiety and PTSD cannot yield a PTSD-specific effect unless a PTSD stratum is reported.

Quantitative anchors

Measure Estimate Population/method Source
Early crossover prazosin n=10; mean 9.5 mg bedtime Positive; very small veteran sample (Raskind 2003, PMID 12562588)
Parallel prazosin n=40; mean ~13 mg/day Positive veteran trial (Raskind 2007, PMID 17069768)
PACT prazosin re-test n=304; 13 VA centres Three primary outcomes null (Raskind 2018, PMID 29414272)
PACT blood pressure −6.7 mm Hg Between-group supine systolic change at week 10 (Raskind 2018, PMID 29414272)
PACT suicidal ideation AE 8% vs 15% Prazosin vs placebo; not evidence of prevention (Raskind 2018, PMID 29414272)
Prazosin, pooled g=0.61 nightmares; 0.81 PTSD symptoms; 0.85 sleep quality 7 prazosin + 8 IRT trials; N=1,078 (Yücel 2020, PMID 31855732)
IRT, pooled g=0.51 nightmares; 0.31 PTSD symptoms; 0.51 sleep quality Same meta-analysis; no significant IRT–prazosin difference (Yücel 2020, PMID 31855732)
IRT anchoring RCT nights with nightmares d=1.24; nightmares/week d=0.85 168 women; 114 completed follow-up (Krakow 2001, PMID 11476655)
Nightmare network meta-analysis prazosin and IRT the only effective interventions 29 RCTs; 14 interventions; n=2,214 (Zhang 2022, PMID 35661755)
Active-duty prazosin RCT positive on nightmares, sleep and global function n=67; 15 weeks (Raskind 2013, PMID 23846759)
Baseline standing systolic BP +14-point CAPS reduction per 10 mm Hg under prazosin (P=.002) Secondary analysis; 32 prazosin, 35 placebo (Raskind 2016, PMID 27320368)
CBT-I before CPT greater 6- and 20-week reductions vs attention control n=110 interpersonal-violence survivors (Pigeon 2022, PMID 34265777)
CBT-I integrated with PE no PTSD difference vs sleep hygiene + PE (P=.844) n=94 veterans (Colvonen 2025, PMID 40488726)

Evidence ledger

The ledger lists the live-retrieved records used to bound this page. Inclusion does not make every record equally probative; design, population and comparator remain decisive.

PMID Year Evidence contribution Scope caution
12562588 2003 Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. PTSD-specific record; inspect design and population
17069768 2007 A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. PTSD-specific record; inspect design and population
29414272 2018 Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. PTSD-specific record; inspect design and population
35688992 2022 Pharmacological Management of Nightmares Associated with Posttraumatic Stress Disorder. PTSD-specific record; inspect design and population
34575284 2021 Treatment Guidelines for PTSD: A Systematic Review. Synthesis: preserve included-population and certainty limits
38795401 2024 Pharmacotherapy for sleep disturbances in post-traumatic stress disorder (PTSD): A network meta-analysis. Synthesis: preserve included-population and certainty limits
32813696 2020 Psychological and pharmacological interventions for posttraumatic stress disorder and comorbid mental health problems following complex traumatic events: Systematic review and component network meta-analysis. Synthesis: preserve included-population and certainty limits
39061119 2024 Psychotherapeutic and pharmacological agents for post-traumatic stress disorder with sleep disorder: network meta-analysis. Synthesis: preserve included-population and certainty limits
34992738 2021 Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches. Synthesis: preserve included-population and certainty limits
36613097 2022 The Effects of Pharmacological Treatment of Nightmares: A Systematic Literature Review and Meta-Analysis of Placebo-Controlled, Randomized Clinical Trials. Synthesis: preserve included-population and certainty limits
35905428 2022 The Effect of Intensive Care Unit Diaries on Posttraumatic Stress Disorder, Anxiety, and Depression: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Synthesis: preserve included-population and certainty limits
40243149 2025 Protocol MelatoSom-Kids-PTSD: sleep disturbances in children and adolescents with post-traumatic stress disorder (PTSD) - a randomized double-blind placebo-controlled trial to investigate the efficacy of paediatric prolonged-release melatonin. PTSD-specific record; inspect design and population
39828080 2025 Factors impacting prazosin efficacy for nightmares and insomnia in PTSD patients - a systematic review and meta-regression analysis. Synthesis: preserve included-population and certainty limits
37991966 2023 PHARMACOLOGY OF POST-TRAUMATIC STRESS DISORDER. PTSD-specific record; inspect design and population
41042258 2025 A double-blind, randomized, placebo-controlled trial of doxazosin for posttraumatic distressing dreams and sleep disturbance in men and women with posttraumatic stress. PTSD-specific record; inspect design and population
38941125 2024 Clonidine for post-traumatic stress disorder: a systematic review of the current evidence. Synthesis: preserve included-population and certainty limits
32362287 2021 Prazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis. Synthesis: preserve included-population and certainty limits
40832812 2026 Lucid Dreaming: Not Just Awareness, but Agency. PTSD-specific record; inspect design and population
25036580 2014 Prazosin in the treatment of PTSD. PTSD-specific record; inspect design and population
35554590 2022 Evaluation of suvorexant for trauma-related insomnia. PTSD-specific record; inspect design and population
24612528 2014 Post-traumatic stress disorder--a diagnostic and therapeutic challenge. PTSD-specific record; inspect design and population
39773112 2025 Dream Enactment Behaviour in Post-Traumatic Stress Disorder. PTSD-specific record; inspect design and population
36700311 2023 Quetiapine Treatment for Post-traumatic Stress Disorder: A Systematic Review of the Literature. Synthesis: preserve included-population and certainty limits
27432823 2017 Treatment of Post-Traumatic Stress Disorders with the Alpha-1 Adrenergic Antagonist Prazosin. PTSD-specific record; inspect design and population
35837535 2022 Sleep Management in Posttraumatic Stress Disorder (PTSD): A Systematic Review. Synthesis: preserve included-population and certainty limits
30538593 2018 Management of nightmares in patients with posttraumatic stress disorder: current perspectives. PTSD-specific record; inspect design and population
33552844 2020 Treatment of Sleep Comorbidities in Posttraumatic Stress Disorder. PTSD-specific record; inspect design and population
27828694 2016 Efficacy of Prazosin in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis. Synthesis: preserve included-population and certainty limits
11476655 2001 Imagery rehearsal therapy for chronic nightmares in sexual assault survivors with posttraumatic stress disorder: a randomized controlled trial. Waitlist comparator; 68% follow-up retention
35661755 2022 Efficacy and acceptability of psychotherapeutic and pharmacological interventions for trauma-related nightmares: A systematic review and network meta-analysis. Nightmare outcome, not total PTSD severity
34265777 2022 A Randomized Clinical Trial of Cognitive-Behavioral Therapy for Insomnia to Augment Posttraumatic Stress Disorder Treatment in Survivors of Interpersonal Violence. Sequential design; effects larger for insomnia than PTSD
40488726 2025 Cognitive Behavioral Therapy for Insomnia With Prolonged Exposure Compared to Sleep Hygiene and Prolonged Exposure: A Randomized Controlled Trial. Null on the PTSD contrast; active comparator
23846759 2013 A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Positive RCT preceding the large null trial
27320368 2016 Higher Pretreatment Blood Pressure Is Associated With Greater Posttraumatic Stress Disorder Symptom Reduction in Soldiers Treated With Prazosin. Secondary analysis; hypothesis-generating
30143236 2019 Is Pretreatment Blood Pressure a Marker of Prazosin Response in Posttraumatic Stress Disorder With Comorbid Alcohol Use Disorder? Correspondence; contests the marker in a comorbid sample

Interpretation guardrails

  • Trauma exposure, post-traumatic symptoms, acute stress disorder, DSM-5 PTSD, ICD-11 PTSD and ICD-11 complex PTSD are not interchangeable populations.
  • A mixed-anxiety or transdiagnostic estimate is labelled as such; only a source’s PTSD stratum can be treated as a PTSD effect.
  • Comorbid depression is measured separately and cross-linked to the depression condition; it is not absorbed into PTSD.
  • Waitlist, treatment-as-usual, attention control and active treatment answer different causal questions.
  • Registration, statistical significance and diagnostic loss do not respectively prove completion, clinical importance or functional recovery.
  • This page synthesizes research and does not provide individual medical advice.

Minimum extraction frame for studies on this topic

Field What must be retained Why it changes interpretation
Diagnostic system DSM version, ICD version, full/subthreshold Case mix is not interchangeable
Diagnostic method Structured interview, clinician judgment, self-report cutoff Screening is not diagnosis
Index trauma Type, timing, repetition, direct/indirect/occupational Conditional risk and phenotype differ
Population Civilian, veteran, refugee, child/adolescent, mixed Transportability is empirical
Baseline severity Mean, SD, range and exclusion threshold Ceiling and floor effects alter change
CPTSD status ITQ/ICD-11 definition and DSO score Complexity cannot be inferred from trauma count
Comorbidity Depression, GAD, SUD, pain, TBI measured separately Shared symptoms can distort effects
Comparator Waitlist, usual care, attention, active treatment The estimand changes with comparator
Treatment dose Sessions offered/attended, duration, homework Assignment is not exposure
Outcome Symptoms, diagnosis, response, function, sleep Outcomes are not interchangeable
Time point End point and prespecified follow-up windows Acute benefit may not persist
Missing data Denominator, reasons, imputation and estimand Attrition can bias rank and magnitude
Adverse events Definitions, ascertainment and arm-level counts Absence of reporting is not absence of harm
Therapist/context Training, fidelity, allegiance, setting Delivery is part of the intervention
Funding/conflicts Sponsor role and analytic independence Especially material for proprietary packages

Claims this page does not make

  • It does not infer PTSD from trauma exposure alone.
  • It does not treat a self-report cutoff as equivalent to a structured diagnosis.
  • It does not convert a pooled anxiety-disorder effect into a PTSD effect.
  • It does not convert a depression outcome in a comorbid sample into a PTSD outcome.
  • It does not infer superiority from a statistically significant within-group change.
  • It does not infer equivalence from a non-significant between-group test.
  • It does not infer effectiveness from trial registration or mechanistic plausibility.
  • It does not assume military, civilian, refugee and pediatric estimates transport unchanged.
  • It does not average conflicting estimates that use different definitions.
  • It does not treat lack of adverse-event reporting as evidence of safety.

Evidence-updating triggers

Trigger Required response
New diagnostic revision Recalculate which populations prior estimates represent
New head-to-head RCT Compare against active treatment, not only waitlist
New individual-participant synthesis Revisit effect modifiers and transportability
Registry status change Verify results and linked publication before changing conclusions
Guideline update Separate evidence review from panel recommendation
Regulatory decision Record decision date and source; do not infer from efficacy papers
Safety signal Re-extract denominator, ascertainment and exposure time by arm
Contradictory replication Display estimates side by side; do not average definitions

Evidence updates should preserve the prior estimate and explain why the new study changes—or does not change—the inference.

Open questions

  • What prospectively defined phenotype predicts prazosin response after the PACT null result? (Raskind 2018, PMID 29414272)
  • Does treating insomnia first improve completion of trauma-focused psychotherapy? (Simon 2017, PMID 27432823)
  • Which imagery-rehearsal components are necessary and durable? (Green 2014, PMID 25036580)

References

  1. Raskind MA, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry. 2003;160(2):371-3. PMID 12562588
  2. Raskind MA, et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry. 2007;61(8):928-34. PMID 17069768
  3. Raskind MA, et al. Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. N Engl J Med. 2018;378(6):507-517. PMID 29414272
  4. Geldenhuys C, et al. Pharmacological Management of Nightmares Associated with Posttraumatic Stress Disorder. CNS Drugs. 2022;36(7):721-737. PMID 35688992
  5. Martin A, et al. Treatment Guidelines for PTSD: A Systematic Review. J Clin Med. 2021;10(18):4175. PMID 34575284
  6. Lappas AS, et al. Pharmacotherapy for sleep disturbances in post-traumatic stress disorder (PTSD): A network meta-analysis. Sleep Med. 2024;119:467-479. PMID 38795401
  7. Coventry PA, et al. Psychological and pharmacological interventions for posttraumatic stress disorder and comorbid mental health problems following complex traumatic events: Systematic review and component network meta-analysis. PLoS Med. 2020;17(8):e1003262. PMID 32813696
  8. Huang CY, et al. Psychotherapeutic and pharmacological agents for post-traumatic stress disorder with sleep disorder: network meta-analysis. Ann Med. 2024;56(1):2381696. PMID 39061119
  9. Hoskins MD, et al. Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches. Eur J Psychotraumatol. 2021;12(1):1802920. PMID 34992738
  10. Skeie-Larsen M, et al. The Effects of Pharmacological Treatment of Nightmares: A Systematic Literature Review and Meta-Analysis of Placebo-Controlled, Randomized Clinical Trials. Int J Environ Res Public Health. 2022;20(1):777. PMID 36613097
  11. Gazzato A, et al. The Effect of Intensive Care Unit Diaries on Posttraumatic Stress Disorder, Anxiety, and Depression: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Dimens Crit Care Nurs. 2022;41(5):256-263. PMID 35905428
  12. Rolling J, et al. Protocol MelatoSom-Kids-PTSD: sleep disturbances in children and adolescents with post-traumatic stress disorder (PTSD) - a randomized double-blind placebo-controlled trial to investigate the efficacy of paediatric prolonged-release melatonin. Eur J Psychotraumatol. 2025;16(1):2474375. PMID 40243149
  13. Mendes TP, et al. Factors impacting prazosin efficacy for nightmares and insomnia in PTSD patients - a systematic review and meta-regression analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2025;136:111253. PMID 39828080
  14. Tregub T, et al. PHARMACOLOGY OF POST-TRAUMATIC STRESS DISORDER. Georgian Med News. 2023;(342):122-124. PMID 37991966
  15. Richards A, et al. A double-blind, randomized, placebo-controlled trial of doxazosin for posttraumatic distressing dreams and sleep disturbance in men and women with posttraumatic stress. J Clin Sleep Med. 2025;21(12):2165-2179. PMID 41042258
  16. Marchi M, et al. Clonidine for post-traumatic stress disorder: a systematic review of the current evidence. Eur J Psychotraumatol. 2024;15(1):2366049. PMID 38941125
  17. Reist C, et al. Prazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis. CNS Spectr. 2021;26(4):338-344. PMID 32362287
  18. Ableidinger S, et al. Lucid Dreaming: Not Just Awareness, but Agency. J Sleep Res. 2026;35(2):e70181. PMID 40832812
  19. Green B Prazosin in the treatment of PTSD. J Psychiatr Pract. 2014;20(4):253-9. PMID 25036580
  20. Mellman TA, et al. Evaluation of suvorexant for trauma-related insomnia. Sleep. 2022;45(5):zsac068. PMID 35554590
  21. Frommberger U, et al. Post-traumatic stress disorder--a diagnostic and therapeutic challenge. Dtsch Arztebl Int. 2014;111(5):59-65. PMID 24612528
  22. Asah C, et al. Dream Enactment Behaviour in Post-Traumatic Stress Disorder. Eur J Psychotraumatol. 2025;16(1):2444743. PMID 39773112
  23. Crapanzano C, et al. Quetiapine Treatment for Post-traumatic Stress Disorder: A Systematic Review of the Literature. Clin Psychopharmacol Neurosci. 2023;21(1):49-56. PMID 36700311
  24. Simon PY, et al. Treatment of Post-Traumatic Stress Disorders with the Alpha-1 Adrenergic Antagonist Prazosin. Can J Psychiatry. 2017;62(3):186-198. PMID 27432823
  25. Maher AR, et al. Sleep Management in Posttraumatic Stress Disorder (PTSD): A Systematic Review. Rand Health Q. 2022;9(3):14. PMID 35837535
  26. El-Solh AA Management of nightmares in patients with posttraumatic stress disorder: current perspectives. Nat Sci Sleep. 2018;10:409-420. PMID 30538593
  27. Brownlow JA, et al. Treatment of Sleep Comorbidities in Posttraumatic Stress Disorder. Curr Treat Options Psychiatry. 2020;7(3):301-316. PMID 33552844
  28. Singh B, et al. Efficacy of Prazosin in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis. Prim Care Companion CNS Disord. 2016;18(4):10.4088/PCC.16r01943. PMID 27828694
  29. Krakow B, et al. Imagery rehearsal therapy for chronic nightmares in sexual assault survivors with posttraumatic stress disorder: a randomized controlled trial. JAMA. 2001;286(5):537-45. PMID 11476655
  30. Zhang Y, et al. Efficacy and acceptability of psychotherapeutic and pharmacological interventions for trauma-related nightmares: A systematic review and network meta-analysis. Neurosci Biobehav Rev. 2022;139:104717. PMID 35661755
  31. Pigeon WR, et al. A Randomized Clinical Trial of Cognitive-Behavioral Therapy for Insomnia to Augment Posttraumatic Stress Disorder Treatment in Survivors of Interpersonal Violence. Psychother Psychosom. 2022;91(1):50-62. PMID 34265777
  32. Colvonen PJ, et al. Cognitive Behavioral Therapy for Insomnia With Prolonged Exposure Compared to Sleep Hygiene and Prolonged Exposure: A Randomized Controlled Trial. J Clin Psychiatry. 2025;86(3):24m15584. PMID 40488726
  33. Raskind MA, et al. A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry. 2013;170(9):1003-10. PMID 23846759
  34. Raskind MA, et al. Higher Pretreatment Blood Pressure Is Associated With Greater Posttraumatic Stress Disorder Symptom Reduction in Soldiers Treated With Prazosin. Biol Psychiatry. 2016;80(10):736-742. PMID 27320368
  35. Manhapra A, et al. Is Pretreatment Blood Pressure a Marker of Prazosin Response in Posttraumatic Stress Disorder With Comorbid Alcohol Use Disorder? Biol Psychiatry. 2019;85(3):e11-e12. PMID 30143236
  36. Yücel DE, et al. Comparative efficacy of imagery rehearsal therapy and prazosin in the treatment of trauma-related nightmares in adults: A meta-analysis of randomized controlled trials. Sleep Med Rev. 2020;50:101248. PMID 31855732